XML 115 R12.htm IDEA: XBRL DOCUMENT
v3.26.1

Licensing, Acquisitions and Other Arrangements | 3 Months Ended
--- | ---
Mar. 31, 2026
Licensing, Acquisitions, and Other Arrangements |
Licensing, Acquisitions, and Other Arrangements | Licensing, Acquisitions and Other Arrangements
Acquisition of Nimble Therapeutics, Inc. On January 23, 2025, AbbVie completed its acquisition of Nimble Therapeutics, Inc. (Nimble). Nimble is a biotechnology company dedicated to delivering on the promise of oral peptide therapeutics and its lead asset, an investigational oral peptide IL23R inhibitor in development for the treatment of psoriasis. The aggregate purchase price of $288 million was comprised of a $210 million upfront cash payment and $78 million for the acquisition date fair value of contingent consideration liabilities, for which AbbVie may owe up to $130 million in future payments upon achievement of certain development milestones. The transaction was accounted for as a business combination using the acquisition method of accounting. Other Licensing & Acquisitions Activity Cash outflows related to other acquisitions and investments, net of cash acquired totaled $266 million for the three months ended March 31, 2026 and $334 million for the three months ended March 31, 2025. The following table summarizes acquired IPR&D and milestones expense:
| Three months ended March 31,
(in millions) | 2026 |  | 2025
Upfront charges | $ | 703 |  |  | $ | 246 |
Development milestones | 41 |  |  | 2 |
Acquired IPR&D and milestones | $ | 744 |  |  | $ | 248 |
RemeGen Co., Ltd. In March 2026, AbbVie completed its previously announced license agreement with RemeGen Co., Ltd. (RemeGen). Under the terms of the agreement, AbbVie received an exclusive global license excluding China to develop, manufacture and commercialize RC148 (ABBV-1480), a novel investigational Programmed Cell Death-1 (PD-1)/Vascular Endothelial Growth Factor (VEGF)-targeted bispecific antibody in development for the treatment of multiple advanced solid tumors. The upfront payment of $650 million was recorded in acquired IPR&D and milestones expense in the condensed consolidated statement of earnings in the first quarter of 2026. AbbVie could make additional payments of up to $5.0 billion upon achievement of certain development, regulatory and commercial milestones and pay tiered royalties.

X
- References No definition available. + Details
Name: | abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract
Namespace Prefix: | abbv_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for acquisitions, collaborations and other arrangements of the entity. + References No definition available. + Details
Name: | abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock
Namespace Prefix: | abbv_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration